For patients who have a pathologic complete response (pCR) after 12 weeks of pre-operative THP (single agent taxane plus trastuzumab and pertuzumab), is it safe to omit additional therapy after surgery?
A one-of-a-kind cancer care delivery research trial that offers young women with cancer an assessment of their goals for fertility and family planning to make the most of cancer treatment and preserve future reproductive health